Post by selluwud on Jul 15, 2014 13:21:30 GMT
finance.yahoo.com/news/brainstorm-announces-university-massachusetts-memorial-131500175.html
BrainStorm Announces that University of Massachusetts Memorial Medical Center to Begin Enrolling Patients in Phase 2 ALS Clinical Trial
Accesswire
4 minutes ago
NEW YORK, NY & PETACH TIKVAH, ISRAEL / ACCESSWIRE / July 15, 2014 / BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the University of Massachusetts (UMass) Memorial Medical Center in Worcester, MA will begin enrolling patients into the Company’s randomized, double-bling placebo-controlled phase 2 clinical trial in Amyotrophic Lateral Sclerosis (ALS).UMass Memorial is the second site to become active of the three sites participating in this trial. The other two clinical sites participating in the multi-center trial are Massachusetts General Hospital (MGH), which beganenrolling patients into the trial last month, and the Mayo Clinic, which is expected to become active in the third quarter of 2014. The Dana Farber Cancer Institute's Connell and O'Reilly Cell Manipulation Core Facility will manufacture NurOwn(TM) cells for MGH and UMass Memorial.The principal investigator at UMass Memorial is Professor Robert H. Brown Jr., DPhil, MD, Chair of the Department of Neurology and renowned for his groundbreaking basic and clinical research on neurodegenerative and neuromuscular diseases.Professor Brown commented, "The pilot data from the first NurOwn trials are encouraging; we are delighted to
participate in the follow-up study, an important next step in developing stem cell therapy for ALS. We are hopeful that the early signs of benefit will be repeated in this larger study."
Tony Fiorino, MD, PhD, CEO of BrainStorm, stated, "We are thrilled to welcome UMass as the second active site in this important study.Professor Brown brings an incredible amount of scientific expertise and clinical experience in ALS to this study, and we are grateful for his participation.We acknowledge the hard work for the entire UMass team in preparing for this moment look forward to continuing to work with them as the trial progresses."
The ongoing Phase II trial is a randomized, double-blind, placebo controlled multi-center study designed to evaluate the safety and efficacy of NurOwn(TM) in 48 ALS patients. The primary endpoint of the study is the safety of intrathecal and intramuscular administration of NurOwn(TM). Secondary endpoints include change in the ALS Functional Rating Scale (ALSFRS) and change in slow vital capacity (SVC). For further information, go to www.clinicaltrials.gov.
About UMass Memorial
UMass Memorial Medical Center is the advanced tertiary care referral center for Central New England. The Medical Center offers a full complement of sophisticated technology and support services necessary to provide the region with specialists renowned for their work in areas such as cardiology, cancer, diabetes and orthopedics. To learn more about UMass Memorial, please visit www.umassmemorial.org.
BrainStorm Announces that University of Massachusetts Memorial Medical Center to Begin Enrolling Patients in Phase 2 ALS Clinical Trial
Accesswire
4 minutes ago
NEW YORK, NY & PETACH TIKVAH, ISRAEL / ACCESSWIRE / July 15, 2014 / BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the University of Massachusetts (UMass) Memorial Medical Center in Worcester, MA will begin enrolling patients into the Company’s randomized, double-bling placebo-controlled phase 2 clinical trial in Amyotrophic Lateral Sclerosis (ALS).UMass Memorial is the second site to become active of the three sites participating in this trial. The other two clinical sites participating in the multi-center trial are Massachusetts General Hospital (MGH), which beganenrolling patients into the trial last month, and the Mayo Clinic, which is expected to become active in the third quarter of 2014. The Dana Farber Cancer Institute's Connell and O'Reilly Cell Manipulation Core Facility will manufacture NurOwn(TM) cells for MGH and UMass Memorial.The principal investigator at UMass Memorial is Professor Robert H. Brown Jr., DPhil, MD, Chair of the Department of Neurology and renowned for his groundbreaking basic and clinical research on neurodegenerative and neuromuscular diseases.Professor Brown commented, "The pilot data from the first NurOwn trials are encouraging; we are delighted to
participate in the follow-up study, an important next step in developing stem cell therapy for ALS. We are hopeful that the early signs of benefit will be repeated in this larger study."
Tony Fiorino, MD, PhD, CEO of BrainStorm, stated, "We are thrilled to welcome UMass as the second active site in this important study.Professor Brown brings an incredible amount of scientific expertise and clinical experience in ALS to this study, and we are grateful for his participation.We acknowledge the hard work for the entire UMass team in preparing for this moment look forward to continuing to work with them as the trial progresses."
The ongoing Phase II trial is a randomized, double-blind, placebo controlled multi-center study designed to evaluate the safety and efficacy of NurOwn(TM) in 48 ALS patients. The primary endpoint of the study is the safety of intrathecal and intramuscular administration of NurOwn(TM). Secondary endpoints include change in the ALS Functional Rating Scale (ALSFRS) and change in slow vital capacity (SVC). For further information, go to www.clinicaltrials.gov.
About UMass Memorial
UMass Memorial Medical Center is the advanced tertiary care referral center for Central New England. The Medical Center offers a full complement of sophisticated technology and support services necessary to provide the region with specialists renowned for their work in areas such as cardiology, cancer, diabetes and orthopedics. To learn more about UMass Memorial, please visit www.umassmemorial.org.
